Lyell Immunopharma, Inc (LYEL)

$1.14

-0.03

(-2.56%)▲

Live

Performance

  • $1.10
    $1.15
    $1.14
    downward going graph

    3.95%

    Downside

    Day's Volatility :4.78%

    Upside

    0.87%

    downward going graph
  • $1.06
    $3.26
    $1.14
    downward going graph

    7.02%

    Downside

    52 Weeks Volatility :67.44%

    Upside

    64.98%

    downward going graph

Returns

PeriodLyell Immunopharma, IncSector (Health Care)Index (Russel 2000)
3 Months
-28.22%
3.6%
0.0%
6 Months
-51.45%
10.2%
0.0%
1 Year
-25.0%
19.6%
0.0%
3 Years
-91.58%
16.8%
-23.0%

Highlights

Market Capitalization
302.1M
Book Value
$2.21
Earnings Per Share (EPS)
-0.83
Wall Street Target Price
3.67
Profit Margin
0.0%
Operating Margin TTM
-396369.21%
Return On Assets TTM
-18.85%
Return On Equity TTM
-32.26%
Revenue TTM
54.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-51.9%
Gross Profit TTM
84.7M
EBITDA
-204.5M
Diluted Eps TTM
-0.83
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.83
EPS Estimate Next Year
-0.88
EPS Estimate Current Quarter
-0.2
EPS Estimate Next Quarter
-0.21

Analyst Recommendation

Buy
    70%Buy
    30%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Lyell Immunopharma, Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 221.93%

Current $1.14
Target $3.67

Company Financials

FY19Y/Y Change
Revenue
657.0K
-
Net Income
-121.3M
-
Net Profit Margin
-18.5K%
-
FY20Y/Y Change
Revenue
7.8M
↑ 1080.52%
Net Income
-198.5M
↑ 63.73%
Net Profit Margin
-2.6K%
↑ 15896.28%
FY21Y/Y Change
Revenue
10.7M
↑ 37.31%
Net Income
-285.5M
↑ 43.81%
Net Profit Margin
-2.7K%
↓ 121.03%
FY22Y/Y Change
Revenue
84.7M
↑ 695.15%
Net Income
-4.8M
↓ 98.33%
Net Profit Margin
-5.61%
↑ 2675.15%
FY23Y/Y Change
Revenue
130.0K
↓ 99.85%
Net Income
-234.6M
↑ 4835.46%
Net Profit Margin
-180.5K%
↓ 180480.54%
Q1 FY23Q/Q Change
Revenue
65.0K
↑ 34.34%
Net Income
-132.6M
↓ 5538.77%
Net Profit Margin
-204.0K%
↓ 209086.04%
Q2 FY23Q/Q Change
Revenue
27.0K
↓ 58.46%
Net Income
-63.9M
↓ 51.83%
Net Profit Margin
-236.6K%
↓ 32583.48%
Q3 FY23Q/Q Change
Revenue
25.0K
↓ 7.41%
Net Income
-50.9M
↓ 20.41%
Net Profit Margin
-203.4K%
↑ 33217.63%
Q4 FY23Q/Q Change
Revenue
13.0K
↓ 48.0%
Net Income
-52.9M
↑ 4.08%
Net Profit Margin
-407.2K%
↓ 203741.85%
Q1 FY24Q/Q Change
Revenue
3.0K
↓ 76.92%
Net Income
-60.7M
↑ 14.62%
Net Profit Margin
-2.0M%
↓ 1615079.48%
Q2 FY24Q/Q Change
Revenue
13.0K
↑ 333.33%
Net Income
-45.8M
↓ 24.49%
Net Profit Margin
-352.4K%
↑ 1669856.41%
FY19Y/Y Change
Total Assets
555.6M
-
Total Liabilities
147.6M
-
FY20Y/Y Change
Total Assets
908.3M
↑ 63.47%
Total Liabilities
189.8M
↑ 28.64%
FY21Y/Y Change
Total Assets
1.1B
↑ 24.13%
Total Liabilities
197.6M
↑ 4.1%
FY22Y/Y Change
Total Assets
937.6M
↓ 16.84%
Total Liabilities
104.3M
↓ 47.22%
FY23Y/Y Change
Total Assets
750.0M
↓ 20.0%
Total Liabilities
95.1M
↓ 8.85%
Q1 FY23Q/Q Change
Total Assets
880.5M
↓ 6.09%
Total Liabilities
96.6M
↓ 7.37%
Q2 FY23Q/Q Change
Total Assets
835.4M
↓ 5.12%
Total Liabilities
98.5M
↑ 1.94%
Q3 FY23Q/Q Change
Total Assets
795.0M
↓ 4.83%
Total Liabilities
97.4M
↓ 1.1%
Q4 FY23Q/Q Change
Total Assets
750.0M
↓ 5.66%
Total Liabilities
95.1M
↓ 2.4%
Q1 FY24Q/Q Change
Total Assets
694.2M
↓ 7.44%
Total Liabilities
91.1M
↓ 4.22%
Q2 FY24Q/Q Change
Total Assets
654.1M
↓ 5.77%
Total Liabilities
87.6M
↓ 3.76%
FY19Y/Y Change
Operating Cash Flow
39.5M
-
Investing Cash Flow
-422.4M
-
Financing Cash Flow
351.2M
-
FY20Y/Y Change
Operating Cash Flow
-160.9M
↓ 507.54%
Investing Cash Flow
-273.5M
↓ 35.25%
Financing Cash Flow
476.8M
↑ 35.78%
FY21Y/Y Change
Operating Cash Flow
-126.2M
↓ 21.52%
Investing Cash Flow
-121.6M
↓ 55.55%
Financing Cash Flow
401.2M
↓ 15.84%
FY22Y/Y Change
Operating Cash Flow
-169.6M
↑ 34.3%
Investing Cash Flow
-11.5M
↓ 90.51%
Financing Cash Flow
10.6M
↓ 97.35%
Q1 FY23Q/Q Change
Operating Cash Flow
-46.2M
↑ 14.76%
Investing Cash Flow
32.2M
↓ 31.07%
Financing Cash Flow
-69.0K
↓ 108.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-39.2M
↓ 15.26%
Investing Cash Flow
152.9M
↑ 375.56%
Financing Cash Flow
1.2M
↓ 1833.33%

Technicals Summary

Sell

Neutral

Buy

Lyell Immunopharma, Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lyell Immunopharma, Inc
Lyell Immunopharma, Inc
-18.18%
-51.45%
-25.0%
-91.58%
-93.07%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lyell Immunopharma, Inc
Lyell Immunopharma, Inc
1.78
NA
NA
-0.83
-0.32
-0.19
NA
2.21
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lyell Immunopharma, Inc
Lyell Immunopharma, Inc
Buy
$302.1M
-93.07%
1.78
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Lyell Immunopharma, Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 3.0K → 13.0K (in $), with an average increase of 76.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -60.66M → -45.80M (in $), with an average increase of 32.4% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 107.4%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 136.4%

Institutional Holdings

  • MWG Management Ltd.

    7.88%

  • Orland Properties Ltd

    5.90%

  • BlackRock Inc

    5.27%

  • Vanguard Group Inc

    5.23%

  • Foresite Capital Management IV, LLC

    3.25%

  • T. Rowe Price Associates, Inc.

    3.08%

Company Information

we are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. while enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. our goal is nothing less than to develop curative cell-based immunotherapies for any cancer, with a focus on car-ts and solid tumors.

Organization
Lyell Immunopharma, Inc
Employees
224
CEO
Dr. Richard D. Klausner M.D.
Industry
Services

Discover More

FAQs